Drug Screening Assays, Antitumor
"Drug Screening Assays, Antitumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
MeSH Number(s)
E01.370.225.500.388
E05.200.500.388
E05.242.388
E05.337.550.200
Concept/Terms
Drug Screening Assays, Antitumor- Drug Screening Assays, Antitumor
- Antitumor Drug Screens
- Antitumor Drug Screen
- Drug Screen, Antitumor
- Drug Screens, Antitumor
- Screen, Antitumor Drug
- Screens, Antitumor Drug
- Cancer Drug Tests
- Cancer Drug Test
- Drug Test, Cancer
- Drug Tests, Cancer
- Test, Cancer Drug
- Tests, Cancer Drug
- Anticancer Drug Sensitivity Tests
- Drug Screening Tests, Tumor-Specific
- Drug Screening Tests, Tumor Specific
- Tumor-Specific Drug Screening Tests
- Tumor Specific Drug Screening Tests
- Antitumor Drug Screening Assays
- Anti-Cancer Drug Screens
- Anti Cancer Drug Screens
- Anti-Cancer Drug Screen
- Drug Screen, Anti-Cancer
- Drug Screens, Anti-Cancer
- Screen, Anti-Cancer Drug
- Screens, Anti-Cancer Drug
Below are MeSH descriptors whose meaning is more general than "Drug Screening Assays, Antitumor".
Below are MeSH descriptors whose meaning is more specific than "Drug Screening Assays, Antitumor".
This graph shows the total number of publications written about "Drug Screening Assays, Antitumor" by people in Harvard Catalyst Profiles by year, and whether "Drug Screening Assays, Antitumor" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 4 | 4 |
| 1995 | 0 | 5 | 5 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 3 | 3 |
| 2000 | 1 | 5 | 6 |
| 2001 | 0 | 6 | 6 |
| 2002 | 0 | 5 | 5 |
| 2003 | 1 | 4 | 5 |
| 2004 | 1 | 7 | 8 |
| 2005 | 0 | 5 | 5 |
| 2006 | 0 | 9 | 9 |
| 2007 | 1 | 11 | 12 |
| 2008 | 2 | 9 | 11 |
| 2009 | 3 | 12 | 15 |
| 2010 | 6 | 10 | 16 |
| 2011 | 2 | 14 | 16 |
| 2012 | 7 | 17 | 24 |
| 2013 | 2 | 20 | 22 |
| 2014 | 4 | 28 | 32 |
| 2015 | 8 | 17 | 25 |
| 2016 | 5 | 24 | 29 |
| 2017 | 5 | 19 | 24 |
| 2018 | 2 | 28 | 30 |
| 2019 | 4 | 31 | 35 |
| 2020 | 1 | 26 | 27 |
| 2021 | 0 | 25 | 25 |
| 2022 | 0 | 1 | 1 |
Below are the most recent publications written about "Drug Screening Assays, Antitumor" by people in Profiles.
-
Exploration of mercaptoacetamide-linked pyrimidine-1,3,4-oxadiazole derivatives as DNA intercalative topo II inhibitors: Cytotoxicity and apoptosis induction. Bioorg Med Chem Lett. 2022 06 01; 65:128697.
-
Gwanakosides A and B, 6-Deoxy-a-l-talopyranose-Bearing Aromatic Metabolites from a Streptomyces sp. and Coculture with Pandoraea sp. J Nat Prod. 2022 01 28; 85(1):83-90.
-
Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): in vitro and in vivo studies. J Enzyme Inhib Med Chem. 2021 Dec; 36(1):954-963.
-
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. Proc Natl Acad Sci U S A. 2021 11 09; 118(45).
-
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
-
Synthesis and biological evaluation of N, N-dialkylcarboxy coumarin-NO donor conjugates as potential anticancer agents. Bioorg Med Chem Lett. 2021 11 15; 52:128411.
-
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. Cell Rep. 2021 10 05; 37(1):109788.
-
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Sci Rep. 2021 09 29; 11(1):19343.
-
Tumor microenvironment-based screening repurposes drugs targeting cancer stem cells and cancer-associated fibroblasts. Theranostics. 2021; 11(19):9667-9686.
-
Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. Nat Commun. 2021 09 20; 12(1):5531.